TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9062529

Group type: COMPARATOR
Intervention: Mixed diet containing 100 micrograms phylloquinone/d
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Supplemented diet with 420 micrograms phylloquinone/d on days 6 through 10
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Supplemented diet with 420 micrograms phylloquinone/d
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mixed diet after supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mixed diet
Number of subjects: 9
Study: 7956752

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resumption of treatment during follow-up
Number of subjects: 0
Study: 2837046

Group type: EXPERIMENTAL
Intervention: Indomethacin 1% ophthalmic solution (one drop the evening before surgery and one drop 45 minutes before surgery)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard preoperative dilation regime (no indomethacin)
Number of subjects: 27
Study: 29186984

Group type: EXPERIMENTAL
Intervention: Healthy eating intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 151
Study: 27733560

Group type: EXPERIMENTAL
Intervention: Inhaled CVT‐301 (50 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral carbidopa/levodopa (25 mg/100 mg)
Number of subjects: 24
Study: 23347336

Group type: COMPARATOR
Intervention: Preoperatively 2 g of amoxycillin 1 h before surgery (positive control, PC)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Postoperatively 2 g of amoxycillin immediately following surgery (test 1, T1)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Preoperatively 2 g of amoxycillin 1 h before and 500 mg thrice daily on days 2 and 3 after surgery (test 2, T2)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Preoperatively 2 g of placebo 1 h before surgery (negative control, NC)
Number of subjects: 329
Study: 23386557

Group type: EXPERIMENTAL
Intervention: Guided self-help interventions
Number of subjects: 0
Study: 21458404

Group type: EXPERIMENTAL
Intervention: Exposure plus Safety Behaviour (E + SB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 80
Study: 18299694

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium and plain vitamin D3 supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General measurements (low dose and short period of glucocorticoids)
Number of subjects: 0
Study: 16805710

Group type: EXPERIMENTAL
Intervention: Platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy in resected stage III NSCLC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gene expression profiling studies
Number of subjects: 0
Study: 12788409

Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion with melphalan
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Prophylactic isolated limb perfusion
Number of subjects: 1038
Study: 11061252

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active placebo (low-dose lorazepam)
Number of subjects: 19
Study: 9366102

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Trandolapril 2 mg
Number of subjects: 128
Study: 8398512

Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring (group I)
Number of subjects: 736

Group type: COMPARATOR
Intervention: No pulse oximetry monitoring (group II)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Follow-up study for patients with WMS scores 10 points less after surgery
Number of subjects: 736
Study: 3615347

Group type: EXPERIMENTAL
Intervention: Clovoxamine 50 mg, 100 mg, 150 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mianserin 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 12
Study: 29381651

Group type: EXPERIMENTAL
Intervention: Acute exercise (EX)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (16 weeks)
Number of subjects: 65
Study: 26724489

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Elevated baseline BNP (> median = 72 ng/L)
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: 1-year BNP levels
Number of subjects: 1197

Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 1197
Study: 25319676

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial TRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRT counseling and sound therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audiological outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory Fast Screen
Number of subjects: 0
Study: 15358440

Group type: COMPARATOR
Intervention: Recombinant human GH (rhGH, Somatropin) replacement therapy for 6 months (Group I)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Open study design with GH treatment for 6 months (Group II)
Number of subjects: 18
Study: 12795775

Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated uniforms
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control uniforms (washed in water)
Number of subjects: 272
Study: 9582849

Group type: EXPERIMENTAL
Intervention: Education about diabetes and frequent periodical checkups
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional insulin therapy (two daily injections of a mixture of regular insulin/NPH)
Number of subjects: 13
Study: 7609279

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.15 mg of Somatropin per kilogram per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle of infusion (Control)
Number of subjects: 20
Study: 1977781

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine, 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Astemizole, 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 416322

Group type: EXPERIMENTAL
Intervention: Clofibate (1 g b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactose placebo (1 g b.i.d.)
Number of subjects: 0
Study: 31537316

Group type: EXPERIMENTAL
Intervention: My Birth Control decision support tool
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard counseling without the tool
Number of subjects: 70
Study: 30567286

Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (2nd quintile)
Number of subjects: 6587

Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (3rd quintile)
Number of subjects: 6587

Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (4th quintile)
Number of subjects: 6587

Group type: EXPERIMENTAL
Intervention: Moderate intake of total LC ω‐3 PUFA (approximately 0.5⁻1 g/day)
Number of subjects: 6587

Group type: EXPERIMENTAL
Intervention: Total seafood consumption
Number of subjects: 6587
Study: 27708129

Group type: EXPERIMENTAL
Intervention: M1 rTMS
Number of subjects: 50

Group type: COMPARATOR
Intervention: DLPFC rTMS
Number of subjects: 50

Group type: COMPARATOR
Intervention: M1 + DLPFC rTMS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Double sham
Number of subjects: 50
Study: 24419108

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) plus surgery
Number of subjects: 422

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 422
Study: 20298509

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 367

Group type: COMPARATOR
Intervention: Control (before enrolment)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 367
Study: 20537722

Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive Therapy (MACT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive Therapy (MACT) + Therapeutic Assessment (TA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study: 18165083

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5%
Number of subjects: 98
Study: 15748130

Group type: EXPERIMENTAL
Intervention: Consultation with a nurse for 45 minutes, including a tutorial discussion on normal sleep patterns and written material.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 268
Study: 11872281

Group type: EXPERIMENTAL
Intervention: Institutions that enrolled >= 5 patients
Number of subjects: 239

Group type: COMPARATOR
Intervention: Institutions that enrolled < 5 patients
Number of subjects: 239
Study: 10028217

Group type: EXPERIMENTAL
Intervention: SBT with social support strategies
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Number of subjects: 166
Study: 7552878

Group type: EXPERIMENTAL
Intervention: Cyclosporine rinse (5 ml, 500 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo rinse (5 ml)
Number of subjects: 14
Study: 2147909

Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dose 11 mg) + Atenolol (100 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Atenolol (100 mg) + Placebo
Number of subjects: 87
Study: 7017122

Group type: EXPERIMENTAL
Intervention: Metronidazole and active neomycin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Metronidazole and placebo neomycin
Number of subjects: 73
Study: 31152762

Group type: EXPERIMENTAL
Intervention: Prominent calorie labelling for all cafeteria products (displayed in bold capitalised Verdana typeface with a minimum font size of 14)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Post-intervention feedback from patrons
Number of subjects: 3
Study: 28183547

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with sufentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil infusion
Number of subjects: 60
Study: 26099195

Group type: EXPERIMENTAL
Intervention: Zn alone group (30 mg ZnSO4 daily)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Combined group (30 mg ZnSO4 plus multivitamins)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Control group (placebo, 270 mg lactose)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Zn alone group
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 675
Study: 23998397

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 21410693

Group type: EXPERIMENTAL
Intervention: Mirror therapy (15 minutes of daily bimanual training with a mirror for 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bimanual training without a mirror (15 minutes daily for 3 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Grasp strength testing behind the mirror
Number of subjects: 10
Study: 19281729

Group type: EXPERIMENTAL
Intervention: New oral topotecan formulation (4 mg dose)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Current oral topotecan formulation (4 mg dose)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: New oral topotecan formulation (4 mg dose) in fed state
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: New oral topotecan formulation (4 mg dose) in fasted state
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Safety data for all subjects (n = 108)
Number of subjects: 108
Study: 17587424

Group type: EXPERIMENTAL
Intervention: Ciclesonide 100 microg
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Ciclesonide 200 microg
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Ciclesonide 400 microg
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 15547701

Group type: EXPERIMENTAL
Intervention: oral doxifluridine
Number of subjects: 12

Group type: COMPARATOR
Intervention: intravenous infusion of 5-FU
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: intravenous infusion of irinotecan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: combination of doxifluridine and irinotecan
Number of subjects: 12
Study: 11573674

Group type: EXPERIMENTAL
Intervention: StyletScope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 0
Study: 9817589

Group type: EXPERIMENTAL
Intervention: Overshadowing+ (OV+)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Overshadowing- (OV-)
Number of subjects: 16
Study: 8067215

Group type: EXPERIMENTAL
Intervention: 7.4 mmHg (1 kPa) continuous positive airway pressure (CPAP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 30% oxygen by mask with ambient airway pressure (Control)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30
Study: 2845349

Group type: EXPERIMENTAL
Intervention: RRV vaccine (10^4 plaque-forming units)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 31675124

Group type: EXPERIMENTAL
Intervention: M2000
Number of subjects: 12
Study: 29382467

Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Alvogyl (positive control)
Number of subjects: 38
Study: 28760801

Group type: EXPERIMENTAL
Intervention: Usual antibiotic treatment with the addition of 8 L of polyethylene glycol (PEG) lavage via nasojejunal tube
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual antibiotic treatment
Number of subjects: 24
Study: 26580743

Group type: EXPERIMENTAL
Intervention: γ-tACS
Number of subjects: 18

Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 18

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 18
Study: 23200785

Group type: EXPERIMENTAL
Intervention: Transcranial laser stimulation (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control (n=20)
Number of subjects: 40
Study: 21515916

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Infliximab re-introduction after cessation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Joint damage progression rate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Predictors for re-introduction of infliximab
Number of subjects: 104

Group type: COMPARATOR
Intervention: Non-smoking, SE-negative patients treated <18 months
Number of subjects: 104
Study: 19081881

Group type: EXPERIMENTAL
Intervention: Elliptical component without holes and sintered beads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemispherical components with more holes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma-spray and small-bead coatings
Number of subjects: 0
Study: 17157114

Group type: EXPERIMENTAL
Intervention: Sumatriptan injection 6 mg
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control (inactive vehicle)
Number of subjects: 784
Study: 14680204

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10 mg/kg after anaesthetic induction, on bypass, and after protamine at the end of bypass (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No drug (group A)
Number of subjects: 120
Study: 10880793

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 10
Study: 8804799

Group type: EXPERIMENTAL
Intervention: Oral fluconazole, 200 mg once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous amphotericin B, 0.3 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous amphotericin B
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral fluconazole
Number of subjects: 31
Study: 1733187

Group type: EXPERIMENTAL
Intervention: Magnesium gluconate 1 gm orally four times daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Magnesium gluconate
Number of subjects: 54
Study: 6467800

Group type: EXPERIMENTAL
Intervention: Nifedipine (rectal infusion at a zero-order rate for 24 hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 6
Study: 31437754

Group type: EXPERIMENTAL
Intervention: encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: encorafenib 300 mg once daily
Number of subjects: 570

Group type: COMPARATOR
Intervention: vemurafenib 960 mg twice daily
Number of subjects: 570
Study: 29595687

Group type: EXPERIMENTAL
Intervention: Glycyrrhizae Decoction for Purging Stomach-Fire (GDPSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of GDPSF and thalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: GDPSF
Number of subjects: 0
Study: 27037499

Group type: EXPERIMENTAL
Intervention: Calorie information provided in a questionnaire
Number of subjects: 119

Group type: COMPARATOR
Intervention: Calorie information in a randomized field experiment
Number of subjects: 119
Study: 25134860

Group type: EXPERIMENTAL
Intervention: Strict glucose control (90-120 mg/dL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liberal glucose control (121-180 mg/dL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both strict and liberal glucose control
Number of subjects: 0
Study: 23185314

Group type: EXPERIMENTAL
Intervention: High-intensity (HI) training (n = 161, 152 completed)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Low-intensity (LI) training (n = 142, 136 completed)
Number of subjects: 303
Study: 20578377

Group type: EXPERIMENTAL
Intervention: Warming‐reinforcing acupuncture combined with rehabilitation training (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rehabilitation training (group B)
Number of subjects: 80
Study: 18096041

Group type: EXPERIMENTAL
Intervention: PFMT combined with RBT
Number of subjects: 106

Group type: COMPARATOR
Intervention: PFMT alone
Number of subjects: 106
Study: 15510191

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12502278

Group type: EXPERIMENTAL
Intervention: I Can Problem Solve (ICPS) program alone
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Combined ICPS and Strengthening Families (SF) program
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: SF parent training only
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Strengthening Families (SF) program
Number of subjects: 655

Group type: COMPARATOR
Intervention: No-treatment controls
Number of subjects: 655
Study: 9661398

Group type: EXPERIMENTAL
Intervention: Health Care Assistants (HCAs) in orthopaedic and medical wards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurses in wards with HCAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nurses in control wards
Number of subjects: 0
Study: 7917368

Group type: EXPERIMENTAL
Intervention: Ondansetron and Lorazepam
Number of subjects: 53
Study: 2802124

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg
Number of subjects: 32
Study: 8749

Group type: EXPERIMENTAL
Intervention: Dibenzepin (Noveril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study: 7001282

Group type: EXPERIMENTAL
Intervention: Glucametacine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 40
Study: 31835206

Group type: EXPERIMENTAL
Intervention: Daclizumab beta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assuming no censored participants were confirmed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assuming all censored participants were confirmed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observed rate multiple imputation (ORMI)
Number of subjects: 0
Study: 30256198

Group type: EXPERIMENTAL
Intervention: Lansoprazole (PPI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27052122

Group type: EXPERIMENTAL
Intervention: Methimazole therapy in subjects with TSH <1.0 μIU/mL
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Observation (untreated) in subjects with TSH <1.0 μIU/mL
Number of subjects: 293

Group type: COMPARATOR
Intervention: Observation (untreated) in subjects with TSH ≥1.0 μIU/mL
Number of subjects: 293
Study: 24581989

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Daily recombinant FSH
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Corifollitropin alfa and Daily recombinant FSH
Number of subjects: 1506
Study: 22415232

Group type: EXPERIMENTAL
Intervention: S-1 (80, 100, or 120 mg per day on days 1-28, every 42 days, 4 courses)
Number of subjects: 1504

Group type: COMPARATOR
Intervention: UFT/LV (UFT, 300 mg m(‐2) per day as tegafur; LV, 75 mg per day on days 1-28, every 35 days, 5 courses)
Number of subjects: 1504
Study: 19458303

Group type: EXPERIMENTAL
Intervention: Medihoney Antibacterial Wound Gel
Number of subjects: 370

Group type: COMPARATOR
Intervention: Mupirocin (control)
Number of subjects: 370
Study: 17505376

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) group work
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 14678367

Group type: EXPERIMENTAL
Intervention: Enhanced patient participation in treatment choice
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standardized treatment protocol
Number of subjects: 210
Study: 11547358

Group type: EXPERIMENTAL
Intervention: PEG-hirudin (polyethylene glycol-hirudin)
Number of subjects: 0
Study: 9888616

Group type: EXPERIMENTAL
Intervention: Haloperidol + vitamin E (3200 IU/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 24